-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Understanding Cold Agglutinin Disease: How Do Emerging Treatment Options Have the Potential to Transform Patient Outcomes?

Sponsor: Sanofi Genzyme
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Anemias, autoimmune disorders, Biological, antibodies, Diseases, Therapies, Immune Disorders
Friday, December 4, 2020: 7:00 AM-10:00 AM
Chair:
Alexander Röth, MD, University of Duisburg-Essen
Disclosures:
Röth: Biocryst: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Alexion Pharmaceuticals Inc.: Consultancy, Honoraria, Research Funding; Apellis: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding.
Speakers:
Ilene C. Weitz, University of Southern California , David J. Kuter, MD, Massachusetts General Hospital and Wilma Barcellini, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Disclosures:
Weitz: Apellis: Consultancy, Honoraria; Alexion: Consultancy, Honoraria, Speakers Bureau. Kuter: Zafgen: Consultancy, Honoraria; UCB: Consultancy, Honoraria; Up-To-Date: Consultancy, Honoraria, Patents & Royalties; Dova: Consultancy, Honoraria; Takeda (Bioverativ): Consultancy, Honoraria, Other, Research Funding; Rigel: Consultancy, Honoraria, Other, Research Funding; Novartis: Consultancy, Honoraria; Momenta: Consultancy, Honoraria; Merck Sharp Dohme: Consultancy, Honoraria; Kyowa-Kirin: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Immunovant: Consultancy, Honoraria; Genzyme: Consultancy, Honoraria; Alnylam: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Agios: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Actelion (Syntimmune): Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Platelet Disorder Support Association: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Immunovant: Other: Travel Expenses, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Argenx: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Amgen: Consultancy, Honoraria, Other: Travel Expenses, Research Funding; Principia: Consultancy, Research Funding; Protalix Biotherapeutics: Consultancy; Shionogi: Consultancy; Protalex: Consultancy, Honoraria, Research Funding; Protalex: Consultancy, Honoraria, Other, Research Funding; Principia Biopharma: Consultancy, Honoraria, Other, Research Funding; Kezar Life Sciences, Inc: Other, Research Funding; CRICO: Consultancy, Honoraria; Caremark: Consultancy, Honoraria; Shire: Consultancy, Honoraria; Shionogi: Consultancy, Honoraria; Sanofi (Genzyme): Consultancy, Honoraria. Barcellini: Bioverativ: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Other: invited speaker , Research Funding; Agios: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Alexion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: invited speaker , Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees.
This activity will bring together renowned experts in Cold Agglutinin Disease (CAD) treatment and clinical research together for an in-depth case-based discussion that will assess the clinical impact of recent and emerging trial data for CAD. A series of case presentations will be presented with clinical trial data tightly integrated to illuminate CAD treatment decisions related to patient and disease characteristics. Adverse events and management will be educationally tied to appropriate presentations. Future directions in the field will also be addressed and considered regarding how recent developments and highly anticipated trials may shape care in the future. Faculty will be present onstage throughout the program. Audience participation will be integrated throughout to encourage interaction with faculty and engagement with the content.
See more of: Satellite Symposia